Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm study of tick-borne encephalitis vaccine in healthy Japanese participants aged 1 year and older
2022-004181-37Phase 3
- Sponsor
- Pfizer
- Start
- Feb 2023
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of FSME-IMMUN in tick-borne encephalitis (TBE), sponsored by Pfizer. Primary endpoint: Primary seropositivity rate (NT titer ≥1:10) in participants aged ≥16 years.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2022-004181-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004181-37.